For further details see:
AbbVie's Vraylar gets approval in Canada to treat bipolar 1, schizophrenia in adultsFor further details see:
AbbVie's Vraylar gets approval in Canada to treat bipolar 1, schizophrenia in adultsMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....
2024-04-30 09:59:20 ET The stock market is where investors trade shares of publicly traded companies. Among various investment options, dividend stocks are popular for their potential to provide income through regular dividend payments. These stocks are often shares of well-established ...
2024-04-29 11:00:06 ET Evan Seigerman from BMO Capital issued a price target of $180.00 for ABBV on 2024-04-29 09:49:00. The adjusted price target was set to $180.00. At the time of the announcement, ABBV was trading at $158.5841. The overall price target consensus is at...